Barclays analyst Carter Gould maintained a Buy rating on Alector (ALEC – Research Report) today and set a price target of $12.00. The company’s shares closed yesterday at $5.20.
According to TipRanks, Gould is a 4-star analyst with an average return of 8.2% and a 54.01% success rate. Gould covers the Healthcare sector, focusing on stocks such as Eli Lilly & Co, Biogen, and Regeneron.
Currently, the analyst consensus on Alector is a Strong Buy with an average price target of $16.20, implying a 211.54% upside from current levels. In a report released yesterday, H.C. Wainwright also reiterated a Buy rating on the stock with a $35.00 price target.
The company has a one-year high of $9.07 and a one-year low of $3.66. Currently, Alector has an average volume of 601.9K.
Based on the recent corporate insider activity of 40 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of ALEC in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Alector (ALEC) Company Description:
Alector, Inc. operates as a clinical-stage biopharmaceutical company. It develops therapeutics for the treatment of neurodegenerative diseases including frontotemporal dementia (FTD), Alzheimer’s disease, and Parkinson’s disease. The company was founded by Asa Abeliovich, Errik B. Anderson, Tillman U. Gerngross, and Arnon Rosenthal in May 2013 and is headquartered in South San Francisco, CA.
